Latest Breaking News On - Efficacy assessor blinded head to phase - Page 1 : comparemela.com

LEVEL UP data presented at RAD 2024 provide additional insight into the phase 3b/4 trial comparing upadacitinib and dupilumab in atopic dermatitis beyond the primary endpoint.

United statesJonathan silverbergHealth scienceDrug administrationGeorge washington university school of medicineAbbvie news centerGeorge washington university jonathan silverbergOffice of the commissionerGeorge washington universityRevolutionizing atopic dermatitisGeorge washington university schoolEczema areaSeverity indexWorst pruritus numerical rating scaleModerate to severe atopic dermatitisEfficacy assessor blinded head to phase